Orkila Capital acquired a minority stake in Cannamedical Pharma, one of the leading independent cannabis wholesalers in Germany and the European Union, for €15m. Jesse Du Bey, founder and Managing Partner of Orkila Capital, says: "We look for leading platforms in massive and evolving consumer markets and have found such an opportunity in Cannamedical. As with our early leading investments in the global health and wellness space and the European craft beer industry, we believe in Cannamedical’s ability to provide customers with an innovate product and help develop the potential of a huge market. Having observed the development of the North American medical cannabis market, we know medical cannabis is an important, organic medicine with few side effects, primarily targeting patients with acute and chronic conditions. Having witnessed the terrible consequences of the opiate prescription wave in the US, we believe Cannamedical can be a key player in helping German healthcare professionals provide millions of consumers with a natural therapy for chronic pain and many other acute conditions."